Home › Clovis Oncology reports lucitanib Phase 1/2a monotherapy study results at ASCO
 

Keywords :   


Clovis Oncology reports lucitanib Phase 1/2a monotherapy study results at ASCO

2014-05-31 19:24:01| Logistics - Topix.net

Clovis Oncology today announced results from an ongoing Phase 1/2a monotherapy study evaluating lucitanib, the Company's novel, potent inhibitor of the tyrosine kinase activity of fibroblast growth factor receptors 1 through 3 , vascular endothelial growth factor receptors 1 through 3 and platelet-derived growth factor receptors alpha and beta .

Tags: results study reports phase

Category:Transportation and Logistics

Latest from this category

All news
08.11Atlantic Tropical Weather Outlook
08.11Eastern North Pacific Tropical Weather Outlook
08.11Hurricane Rafael Graphics
08.11Summary for Hurricane Rafael (AT3/AL182024)
08.11Hurricane Rafael Wind Speed Probabilities Number 21
08.11Atlantic Tropical Weather Outlook
08.11Eastern North Pacific Tropical Weather Outlook
08.11Hurricane Rafael Graphics
Transportation and Logistics »
08.11Trump tariffs could cost UK 22bn of exports
08.11Watchdog to review police handling of Al Fayed abuse claims
08.11Cattle marketing: Its about making the right decisions
08.11Atlantic Tropical Weather Outlook
08.11Eastern North Pacific Tropical Weather Outlook
08.11Statement from the U.S. Green Building Council on the 2024 Election Results
08.11Bolt drivers win right to holiday and minimum wage
08.11INX details acquisition, SpectraGraphics grows and more
More »